1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone has been researched along with haloperidol in 1 studies
Studies (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Trials (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Recent Studies (post-2010) (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Studies (haloperidol) | Trials (haloperidol) | Recent Studies (post-2010) (haloperidol) |
---|---|---|---|---|---|
26 | 0 | 5 | 20,330 | 1,753 | 3,294 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Rasmussen, K | 1 |
1 review(s) available for 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone and haloperidol
Article | Year |
---|---|
CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons.
Topics: Animals; Anxiety; Brain; Cholecystokinin; Dopamine; Haloperidol; Humans; Neurons; Pyrazoles; Receptors, Cholecystokinin; Schizophrenia | 1994 |